These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29138653)

  • 1. The incidence of first-line antiretroviral treatment changes and related factors among HIV-infected sex workers in Nairobi, Kenya.
    Ndakala FN; Oyugi JO; Oluka MN; Kimani J; Norbert Behrens GM
    Pan Afr Med J; 2017; 28():7. PubMed ID: 29138653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs.
    Ndakala FN; Oyugi JO; Oluka MN; Kimani J; Jablonka A; Behrens GM
    Pan Afr Med J; 2016; 25():14. PubMed ID: 28154706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustainability of first-line antiretroviral regimens: findings from a large HIV treatment program in western Kenya.
    Braitstein P; Ayuo P; Mwangi A; Wools-Kaloustian K; Musick B; Siika A; Kimaiyo S
    J Acquir Immune Defic Syndr; 2010 Feb; 53(2):254-9. PubMed ID: 19745752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
    Inzaule S; Otieno J; Kalyango J; Nafisa L; Kabugo C; Nalusiba J; Kwaro D; Zeh C; Karamagi C
    PLoS One; 2014; 9(4):e93106. PubMed ID: 24695108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens.
    Parkes-Ratanshi R; Katende D; Levin J; Wakeham K; Heiner G; Kamali A; Lalloo DG
    J Int Assoc Provid AIDS Care; 2015; 14(5):455-62. PubMed ID: 25425638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
    Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y
    J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Treatment Failure in HIV-Positive Children Receiving Combination Antiretroviral Therapy: Cohort Data From Mozambique and Uganda.
    Costenaro P; Penazzato M; Lundin R; Rossi G; Massavon W; Patel D; Nabachwa S; Franceschetto G; Morelli E; Bilardi D; Nannyonga MM; Atzori A; Mastrogiacomo ML; Mazza A; Putoto G; Giaquinto C
    J Pediatric Infect Dis Soc; 2015 Mar; 4(1):39-48. PubMed ID: 26407356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
    Castelnuovo B; Kiragga A; Kamya MR; Manabe Y
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):59-63. PubMed ID: 20861741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.
    Capeau J; Bouteloup V; Katlama C; Bastard JP; Guiyedi V; Salmon-Ceron D; Protopopescu C; Leport C; Raffi F; Chêne G;
    AIDS; 2012 Jan; 26(3):303-14. PubMed ID: 22089377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of therapy failure among adults on first-line antiretroviral therapy in Asmara, Eritrea: a multicenter retrospective matched case-control study.
    Mengistu ST; Ghebremeskel GG; Ghebrat HB; Achila OO; Yohannes NA; Ghebrenegus AS; Wendmhuney FG; Yeibyo N; Andegiorgish AK; Mesfin AB; Leake N
    BMC Infect Dis; 2022 Nov; 22(1):834. PubMed ID: 36357837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.
    McGrath CJ; Njoroge J; John-Stewart GC; Kohler PK; Benki-Nugent SF; Thiga JW; Etyang A; Chung MH
    J Neurovirol; 2012 Jun; 18(3):200-4. PubMed ID: 22528481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug reactions associated with antiretroviral therapy in South Africa.
    Birbal S; Dheda M; Ojewole E; Oosthuizen F
    Afr J AIDS Res; 2016 Sep; 15(3):243-8. PubMed ID: 27681148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Taejaroenkul S; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2012 Apr; 31(4):384-8. PubMed ID: 22124211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
    Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
    Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
    Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
    Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.